Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

GENPREX (GNPX) News Today

GENPREX logo
$0.17 +0.00 (+1.89%)
Closing price 04:00 PM Eastern
Extended Trading
$0.17 +0.00 (+0.17%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

GNPX Latest News

Genprex receives notice of allowance for multiple patents for Reqorsa
August 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/genprex-receives-notice-of-allowance-for-multiple-patents-for-reqorsa/ar-AA1KK2QK
Genprex Secures Patent Allowances for Gene Therapy
August 18, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-secures-patent-allowances-for-gene-therapy?utm_source=marketbeat.com&utm_medium=referral
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
August 18, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-receives-notice-of-allowance-for-multiple-patents-for-reqorsa-gene-therapy-with-pd-l1-and-pd-1-antibodies-to-treat-cancers-302531812.html
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
August 4, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-issues-stockholder-letter-and-provides-2025-corporate-update-302519361.html
Genprex, Inc. (GNPX) Latest Stock News & Headlines - Yahoo Finance
June 27, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/GNPX/news/
Genprex reports positive results from diabetes gene therapy study
June 25, 2025  |  investing.comhttps://www.investing.com/news/company-news/genprex-reports-positive-results-from-diabetes-gene-therapy-study-93CH-4108308
Genprex Announces Positive Preclinical Results for GPX-002
June 24, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-announces-positive-preclinical-results-for-gpx-002?utm_source=marketbeat.com&utm_medium=referral
Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
June 24, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-present-positive-preclinical-research-on-diabetes-gene-therapy-at-the-2025-american-diabetes-association-85th-scientific-sessions-302488449.html
Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions
June 23, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-present-research-on-non-viral-approach-to-diabetes-gene-therapy-using-lipid-nanoparticle-delivery-system-at-the-2025-american-diabetes-association-85th-scientific-sessions-302486639.html
Genprex to Participate at BIO 2025 International Convention
June 3, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-to-participate-at-bio-2025-international-convention-302471510.html
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
May 29, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-to-present-trial-design-of-acclaim-3-clinical-trial-evaluating-reqorsa-gene-therapy-in-small-cell-lung-cancer-at-2025-asco-annual-meeting-302467469.html
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
May 28, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-present-positive-preclinical-data-on-diabetes-gene-therapy-at-the-asgct-28th-annual-meeting-302466749.html
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes
May 7, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-signs-sponsored-research-agreement-with-the-university-of-pittsburgh-to-study-diabetes-gene-therapy-in-type-1-and-type-2-diabetes-302448283.html
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma
May 6, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-signs-exclusive-license-to-additional-gene-therapy-technology-with-uthealth-houston-for-the-treatment-of-glioblastoma-302446805.html
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
April 30, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-report-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-ras-inhibitor-resistant-lung-cancer-at-the-2025-aacr-annual-meeting-302442267.html
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
April 29, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-diabetes-gene-therapy-at-the-asgct-28th-annual-meeting-302440907.html
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma
April 28, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-signs-exclusive-technology-license-agreement-with-new-york-university-langone-health-for-the-treatment-of-mesothelioma-302438772.html
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
April 24, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-selected-to-present-trial-design-of-acclaim-3-clinical-trial-evaluating-reqorsa-gene-therapy-in-small-cell-lung-cancer-at-2025-asco-annual-meeting-302435855.html
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings
April 22, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-announces-research-collaborators-abstract-published-in-cancer-research-supplement-proceedings-302432197.html
Genprex reports progress in lung cancer gene therapy
March 28, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/genprex-reports-progress-in-lung-cancer-gene-therapy-93CH-3998168
Genprex to present results preclinical data from Reqorsa study
March 27, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genprex-to-present-results-preclinical-data-from-reqorsa-study-1034517918
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
March 26, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-annual-meeting-302411682.html
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
March 25, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-selected-to-present-positive-preclinical-data-on-diabetes-gene-therapy-at-the-2025-american-diabetes-association-85th-scientific-sessions-302410302.html
CS Diagnostics (OTCQB: CSDX) CS-Protect Hydrogel FDA Approval on Fasttrack – GNPX, BON, SES, BETRF – Stocks to Watch Now!
March 18, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/31461866/cs-diagnostics-otcqb-csdx-cs-protect-hydrogel-fda-approval-on-fasttrack-gnpx-bon-ses-betrf-stocks-to-watch-now/
Genprex to Participate at BIO Europe Spring 2025
March 4, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-to-participate-at-bio-europe-spring-2025-302391082.html
Genprex announces advancement of diabetes program, strategic collaboration
February 19, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genprex-announces-advancement-of-diabetes-program-strategic-collaboration-1034379959
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
February 19, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-advances-diabetes-program-with-addition-of-research-focused-on-non-viral-delivery-system-302378701.html
Genprex announces advancement of its diabetes gene therapy program
February 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genprex-announces-advancement-of-its-diabetes-gene-therapy-program-1034373697
Genprex Provides Update on Diabetes Gene Therapy Program
February 18, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-provides-update-on-diabetes-gene-therapy-program-302377772.html
Genprex’s Oncoprex included in lung cancer therapy
February 13, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genprex-s-oncoprex-included-in-lung-cancer-therapy-1034356426
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
February 13, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-find-nprl2-gene-therapy-using-oncoprex-delivery-system-is-a-potential-treatment-for-anti-pd1-resistant-non-small-cell-lung-cancer-302375899.html
Genprex faces Nasdaq delisting over stock price, equity issues
February 12, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/genprex-faces-nasdaq-delisting-over-stock-price-equity-issues/ar-AA1yUfnR
Genprex doses first subject in expansion part of lung cancer gene therapy trial
January 24, 2025  |  msn.comhttps://www.msn.com/en-us/science/genetics/genprex-doses-first-subject-in-expansion-part-of-lung-cancer-gene-therapy-trial/ar-AA1xOGl4
Genprex announces first patient dosed with Regorsa in Phase 2 lung cancer study
January 24, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genprex-announces-first-patient-dosed-with-regorsa-in-phase-2-lung-cancer-study-1034260864
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
January 23, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-announces-first-patient-dosed-in-phase-2-expansion-portion-of-acclaim-3-clinical-study-of-reqorsa-gene-therapy-in-combination-with-tecentriq-to-treat-small-cell-lung-cancer-302358445.html
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-to-participate-at-the-43rd-annual-jp-morgan-healthcare-conference-302342275.html
Genprex receives Safety Review Committee approval to advance Acclaim-3 trial
December 17, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genprex-receives-safety-review-committee-approval-to-advance-acclaim-3-trial-1034142091
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
December 16, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-receives-safety-review-committee-approval-to-advance-to-phase-2-portion-of-acclaim-3-clinical-trial-of-reqorsa-gene-therapy-in-combination-with-tecentriq-in-extensive-stage-small-cell-lung-cancer-302332325.html
Genprex signs exclusive license agreement with University of Michigan
November 20, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genprex-signs-exclusive-license-agreement-with-university-of-michigan-1034043949
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
November 20, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-signs-exclusive-license-to-additional-gene-therapy-technologies-with-the-university-of-michigan-for-the-treatment-of-lung-cancer-302311506.html
Genprex to present positive preclinical data from Reqorsa Gene Therapy study
November 6, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genprex-to-present-positive-preclinical-data-from-reqorsa-gene-therapy-study-1033954008
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
November 5, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-present-positive-preclinical-data-on-reqorsa-gene-therapy-at-the-society-for-immunotherapy-of-cancer-2024-annual-meeting-302296343.html
Genprex to Participate in 2024 BIO Europe Conference
October 31, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-to-participate-in-2024-bio-europe-conference-302292668.html
Looking Into Genprex's Recent Short Interest
October 30, 2024  |  benzinga.comhttps://www.benzinga.com/insights/short-sellers/24/10/41579221/looking-into-genprexs-recent-short-interest
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma
October 28, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-mesothelioma-and-glioblastoma-302288226.html
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive
October 24, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-announces-sponsored-research-agreement-with-the-university-of-michigan-rogel-cancer-center-and-lung-cancer-study-collaboration-with-alk-positive-302285715.html
Genprex (NASDAQ:GNPX) Stock Quotes, Forecast and News Summary
October 22, 2024  |  benzinga.comhttps://www.benzinga.com/quote/GNPX
Genprex advances dose in lung cancer trial
October 17, 2024  |  investing.comhttps://www.investing.com/news/company-news/genprex-advances-dose-in-lung-cancer-trial-93CH-3663620
Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
October 15, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-receives-safety-review-committee-approval-to-advance-to-highest-dose-group-in-phase-1-portion-of-acclaim-3-clinical-trial-of-reqorsa-gene-therapy-in-combination-with-tecentriq-in-extensive-stage-small-cell-lung-cancer-302276249.html
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 10, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-at-the-2024-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics-302272661.html
Get GENPREX News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GNPX Media Mentions By Week

GNPX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GNPX
News Sentiment
▼
1.88

0.98
▲
Average
Medical
News Sentiment

GNPX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GNPX Articles
This Week
▼
1

1
▲
GNPX Articles
Average Week

Get the Latest News and Ratings for GNPX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GENPREX and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:GNPX) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...
Brownstone Research | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...
Crypto 101 Media | Sponsoredtc pixel